Dr Plesner presents, at a press conference at ASH 2015, updated results of a phase I/II study (GEN503) looking at daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Read the news story and watch the video interview for more information.